VERA

Vera Therapeutics, Inc. Class A Common Stock

39.94

USD

VERA Earnings Reports

Positive Surprise Ratio

VERA beat 6 of 20 last estimates.

30%

Next Report

Date of Next Report

May 04, 2026

Estimate for Q1 26 (Revenue/ EPS)

-$1.36

Implied change from Q4 25 (Revenue/ EPS)

-2.16%

Implied change from Q1 25 (Revenue/ EPS)

+67.90%

Vera Therapeutics, Inc. Class A Common Stock earnings per share and revenue

On Feb 26, 2026, VERA reported earnings of -1.39 USD per share (EPS) for Q4 25, missing the estimate of -1.30 USD, resulting in a -6.33% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -1.63% price change (close before vs. close after earnings).

Looking ahead to Q1 26, 11 analysts forecast an EPS of -1.36 USD, with revenue projected to reach -- USD, implying an decrease of -2.16% EPS, and increase of 0.00% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Mineralys Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.54

Actual

-$0.40

Surprise

+26.40%

Corvus Pharmaceuticals, Inc.

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.13

Actual

-$0.15

Surprise

-13.72%

Pharming Group N.V. ADS, each representing 10 ordinary shares

Report Date

Mar 12, 2026 For Q4 25

Estimate

$0.00

Actual

$0.01

Surprise

+16.28%

ADC Therapeutics SA

Report Date

Mar 10, 2026 For Q4 25

Estimate

-$0.27

Actual

-$0.04

Surprise

+85.39%

Kamada Ltd

Report Date

Mar 11, 2026 For Q4 25

Estimate

$0.07

Actual

$0.06

Surprise

-24.15%

Allogene Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.22

Actual

-$0.17

Surprise

+22.73%

Molecular Partners AG - ADR

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.34

Actual

-$0.32

Surprise

+7.09%

Whitehawk Therapeutics, Inc. Common Stock

Report Date

Mar 12, 2026 For Q4 25

Estimate

-$0.15

Actual

-$0.34

Surprise

-116.42%

Codexis, Inc.

Report Date

Mar 11, 2026 For Q4 25

Estimate

-$0.04

Actual

$0.11

Surprise

+357.01%

Spruce Biosciences, Inc. Common Stock

Report Date

Apr 13, 2026 For Q4 25

Estimate

-$8.14

Actual

Surprise

FAQ

What were Vera Therapeutics, Inc. Class A Common Stock's earnings and revenue for the latest quarter Q4 2025?

For Q4 2025, Vera Therapeutics, Inc. Class A Common Stock reported EPS of -$1.39, missing estimates by -6.33%, and revenue of $0.00, 0% as expectations.

How did the market react to Vera Therapeutics, Inc. Class A Common Stock's Q4 2025 earnings?

The stock price moved down -1.63%, changed from $42.37 before the earnings release to $41.68 the day after.

When is Vera Therapeutics, Inc. Class A Common Stock expected to report next?

The next earning report is scheduled for May 04, 2026.

What are the forecasts for Vera Therapeutics, Inc. Class A Common Stock's next earnings report?

Based on 11 analysts, Vera Therapeutics, Inc. Class A Common Stock is expected to report EPS of -$1.36 and revenue of -- for Q1 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.